Morgan Stanley
LBRX

Morgan Stanley’s LB Pharmaceuticals LBRX Stock Holding History

Morgan Stanley’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
47,280
+22,639
+92% +$522K ﹤0.01% 5059
2025
Q4 		$549K Buy
24,641
+15,036
+157% +$263K ﹤0.01% 5460
2025
Q3 		$152K Buy
+9,605
New +$152K ﹤0.01% 5991

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley's LBRX Position: Q1 2026 in Review

Morgan Stanley increased its LB Pharmaceuticals (LBRX) stake by 92% in Q1 2026, buying an estimated $522K and bringing the position to 47,280 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #5059.

Morgan Stanley first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Morgan Stanley held 47,280 shares of LB Pharmaceuticals worth $1.17M as of Q1 2026.
  • Morgan Stanley bought 22,639 LB Pharmaceuticals shares in Q1 2026, an estimated $522K.
  • LB Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5059 holding.
  • Morgan Stanley first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.